Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.15 USD
-4.21%
Market Closed
Updated:
Apr 20, 2024
Sonoma Pharmaceuticals Inc
Operating Income
Last
Value
3-Years CAGR
5-Years CAGR
|
Sonoma Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Operating Income
$-4.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$12.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Sonoma Pharmaceuticals Inc's Operating Income?
Operating Income
-4.1m
USD
-4.1m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Operating Income amounts to -4.1m USD.
What is Sonoma Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
2%
2%
Over the last year, the Operating Income growth was 34%. The average annual Operating Income growth rates for Sonoma Pharmaceuticals Inc have been -5% over the past three years , 21% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
